Lennard, L., Cartwright, C., Wade, R., Richards, S., Mitchell, C., Kinsey, S., . . . Vora, A. (2010). The thiopurine methyltransferase TPMT *1/*3A genotype is associated with a better treatment outcome in the UK ALL97 trial for childhood acute lymphoblastic leukaemia; TPMT heterozygosity is not associated with secondary cancers.
Παραπομπή σε μορφή Chicago (17η εκδ.)Lennard, L., C. Cartwright, R. Wade, S. Richards, C. Mitchell, S. Kinsey, T. Eden, J. Lilleyman, και A. Vora. The Thiopurine Methyltransferase TPMT *1/*3A Genotype Is Associated with a Better Treatment Outcome in the UK ALL97 Trial for Childhood Acute Lymphoblastic Leukaemia; TPMT Heterozygosity Is Not Associated with Secondary Cancers. 2010.
Παραπομπή σε μορφή MLA (9th εκδ.)Lennard, L., et al. The Thiopurine Methyltransferase TPMT *1/*3A Genotype Is Associated with a Better Treatment Outcome in the UK ALL97 Trial for Childhood Acute Lymphoblastic Leukaemia; TPMT Heterozygosity Is Not Associated with Secondary Cancers. 2010.